-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SZHxYdcwzDENfTs4TdfQIrs+gxLDZ1gnKWiY6C1wwv0fCTXTr5XRvye/sNoodYWg kifphM3aQ5iplO3arGGBtg== 0000912057-02-036830.txt : 20020925 0000912057-02-036830.hdr.sgml : 20020925 20020925144125 ACCESSION NUMBER: 0000912057-02-036830 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20020920 ITEM INFORMATION: Other events FILED AS OF DATE: 20020925 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TRANSKARYOTIC THERAPIES INC CENTRAL INDEX KEY: 0000885259 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 043027191 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-21481 FILM NUMBER: 02771983 BUSINESS ADDRESS: STREET 1: 195 ALBANY ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6173490200 8-K 1 a2089998z8-k.txt FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): SEPTEMBER 20, 2002 --------------------------- TRANSKARYOTIC THERAPIES, INC. -------------------------------------------------------------------------- (Exact Name of Registrant as Specified in its Charter) DELAWARE --------------------------------------------------------------- (State or Other Jurisdiction of Incorporation) 000-21481 04-3027191 -------------------------- ---------------------------------- (Commission File Number) (IRS Employer Identification No.) 195 ALBANY STREET, CAMBRIDGE, MASSACHUSETTS 02139 - -------------------------------------------------------------------------------- (Address of Principal Executive Offices) (Zip Code) (617) 349-0200 ------------------------------------------------------ Registrant's Telephone Number, Including Area Code NOT APPLICABLE ---------------------------------------------------------------------- (Former Name or Former Address, if Changed Since Last Report) Item 5. OTHER EVENTS. ------------ On September 20, 2002, Transkaryotic Therapies, Inc. ("TKT") announced that the Endocrinologic and Metabolic Drugs Advisory Committee will not meet as scheduled on September 26 and 27, 2002 to consider TKT's Replagal(TM) (agalsidase alfa) enzyme replacement therapy for Fabry Disease and a competing product developed by Genzyme Corporation. The Food and Drug Administration has postponed the Advisory Committee meetings due to administrative reasons until later this year. -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 25, 2002 REGISTRANT TRANSKARYOTIC THERAPIES, INC. By: /s/ Daniel E. Geffken ------------------------------------- Daniel E. Geffken Senior Vice President, Finance and Chief Financial Officer -3- -----END PRIVACY-ENHANCED MESSAGE-----